3 deaths: Victim screams for help after accident; onlookers click selfies till he dies

Kanpur, Jul 8: The Special Task Force (STF) shot dead Amar Dubey in an encounter in Maudaha on Wednesday morning. Amar, a right hand man of gangster Vikas Dubey, who shot dead eight police personnel on Friday last, figured prominently in the list of wanted persons released by the Kanpur police on Tuesday.

He was a named accused in the massacre.

According to STF sources, the police team had received a tip off about Amar's presence in the district and when they tried to close in on him, the criminal opened fire on them, He was killed in retaliatory firing around 6.30.a.m,

Amar was reportedly heading towards the house of one of his relatives in Maudaha area.

"We asked him to surrender but he opened fire at us and was killed when we returned the fire," said an STF official.

Earlier, he had been hiding in Faridabad but moved out after police pressure increased there.

Amar Dubey was a trusted accomplice of Vikas Dubey and the police had announced a reward of Rs 25,000 on him after the Kanpur massacre.

Incidentally, reports claim that Vikas Dubey was also seen at a hotel in Faridabad on Tuesday night but fled before the police could close in on him.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.